tbuckley/cabot-search huggingface dataset:
Biology of Hepatocellular Neoplasia In the Mouse. I. Histogenesis of Safrole-Induced Hepatocellular Carcinoma&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN4"&gt;4&lt;/xref&gt;
Authors: Michael M. Lipsky, David E. Hinton, James E. Klaunig, Benjamin F. Trump
 7
Journal: JNCI Journal of the National Cancer Institute (1981)

A sequential, histologic analysis of the livers of male BALB/c mice chronically fed the hepatocarcinogen safrole (4,000 ppm) was performed at 2, 4, 8, 16, 24, 36, 52, and 75 weeks. The transplantability of selected lesions to syngeneic hosts was also assessed. Histopathologic liver alterations at 2, 4, 8, and 16 weeks induced hypertrophy of centrolobular hepatocytes, oval cell proliferation, fatty change in periportal hepatocytes, including basophilic, acidophilic, and clear cell, were noted. At 36 and 52 weeks, hepatocellular adenomas occurred in 4 of 10 and 7 of 10 mice, respectively. At 75 weeks they occurred in 5 of 5 mice. Adenomas were larger than a lobule in diameter compressed the adjacent parenchyma, and distorted the hepatic architecture. Individual adenomas were composed of a mixture of basophilic, acidophilic, clear, and lipid-laden cells, arranged in disorganized cords, one to three cells in thickness. None of the 10 adenomas tested grew upon subcutaneous transplantation into syngeneic hosts. Hepatocellular carcinomas (HPC) developed in 2 of 10 safrole-exposed mice at 52 weeks and 3 of 5 mice at 75 weeks. These lesions were large, multilobed and, unlike adenomas, seemed to invade adjacent parenchyma. The HPC were heterogeneous in cell composition. Their architecture was disorganized with trabeculae of 1-10 or more cells in thickness. No central veins or portal tracts were seen. All HPC proliferated when transplanted into syngeneic hosts. The results of this study demonstrated a sequential development of altered hepatocyte populations leading to HPC in safrole-treated mice. The transplantability of HPC indicated their malignant nature.
Cross-cultural comparison of British and American psychiatric emergencies
Authors: E L Bassuk, R Winter, R Apsler
Journal: American Journal of Psychiatry (1983)

The authors compare patient characteristics in a psychiatric emergency setting in the United States with a similar service in the United Kingdom. They found that despite many significant differences in nonclinical variables, the severity of clinical symptoms did not differentiate between the two groups. In both countries, it was not the degree of psychopathology but the lack of an available support network, an inability to engage the patient in the system, and a history of serious chronic maladjustment that led to the majority of "emergency" visits. The authors conclude that use of an emergency service sensitivity mirrors the gaps in health care delivery.
P-133 Carcinoma of the amulla of vater: factors predictive of survival
Authors: J. Martinez-Galán, L. Ochoa, V. Amezcua, C. Gonzalez, J. Ruiz-Vozmediano, L. Castillo, V. Conde, J. García-García, J.A. Ortega, J.R. Delgado
Journal: Annals of Oncology (2015)
The Influence Of KIR Haplotype In ITP Incidence, Treatment Response and Bleeding Symptoms
Authors: Bethan Psaila, Nayla Boulad, Emily Leven, Naznin Haq, Christina Soo Lee, Shehzad Ahmad, Ruhena Sargent, Kate Stringaris, David Marin, Katayoun Rezvani, James B. Bussel, Nichola Cooper
Journal: Blood (2013)
Utility and Impact Of Early t(15;17) Identification By Fluorescence In Situ Hybridization (FISH) In Clinical Decision Making For Patients With Acute Promyelocytic Leukemia (APL)
Authors: Abhishek Mangaonkar, Vamsi Kota, Amyn Rojiani, Anand Jillella, Ravindra B. Kolhe
Journal: Blood (2013)
Professional Prospects
Authors: R. Lewis
Journal: BMJ (1952)

Struggling with the problems precipitated by the National Health Scheme, the doctor may often be tempted to think that his difficulties are unique.Lawyers, architects, engineers, accountants, schoolmasters, and artists, he may concede, all have their troubles-but, whatever they are, they are not likely to have much bearing on medical professional problems, whose solu- tion can be sought only by doctors wrestling alone with their professional consciences or collectively with the Ministry of Health.But though it is no doubt true that only doctors can solve the problems and resolve the dilemmas which face their profession, a study of the con- temporary difficulties of all the professions suggests that doctors share many of their perplexities with lawyers, accountants, engineers, and so on; and that in shaping their course for the future all the professions can gain greatly from a common awareness of each other's position.For the same social tendencies which have made a national health service inevitable have been changing the status and prospects of the other professions.The basic objectives of nearly all professions are the same.May they not have a good deal that is useful, when planning action, to learn from each other ?May they not have, even, interests that they should defend together rather than separately ?Industrial Revolution in Medicine The National Health Service is the latest development in the long social history of medicine.In the past hundred years medicine has undergone an industrial revolution analogous to that undergone by other techniques and callings.The general practitioner has sur- vived, as the hand-loom weaver has not (except in Harris), but a large part of the functions he discharged a century ago have been taken over by the organized medical factory-that is, the hospital and clinic-where specialists of many sorts, not all of them doctors, co- operate to bring any part of the whole range of' medical science to bear on every single patient, which would now be impossible for one practitioner alone.In these circumstances the G.P. tends to become a sort of preliminary first-aid casualty-clearing station, plus an organ- izing and educational centre; anything " big " goes to the " health factory."The G.P.'s function, however, remains a key one-but it has demonstrably changed.
EPIG-13ROBUST MGMT METHYLATION DETECTION USING 450k ARRAY IN CIMP-NEGATIVE GBM
Authors: Yasin Mamatjan, Gelareh Zadeh, Erik Sulman, Kenneth Aldape
Journal: Neuro-Oncology (2015)

Robust and accurate testing of MGMT methylation as a predictive biomarker is of vital importance to predict response to temozolomide in GBM patients. Although various approaches were published previously for DNA methylation based cancer classification, there is a need for improving accuracy, reproducibility and clarity. To achieve this, we set guidelines for reproducibility and created a classification framework for predicting MGMT methylation efficiently using predictive modeling and validation. We have utilized Illumina 450k genome-wide methylation signatures to identify CpGs whose methylation status correlates with MGMT status. We reflected realistic clinical aspect by separating training and validation dataset to avoid biased feature selection, and performed cross validation (2-level 8-fold). Feature extraction was performed by ANOVA to identify biomarkers that reflect the methylation status of MGMT gene for GBM classification. Samples that showed CIMP-positive profiles by 450k were excluded, given the confounding of CIMP status with MGMT methylation. We examined 450k data from 191 samples of GBM which were tested on the Illumina 450k array at 2 centers and compared array data with MGMT methylation status determined by methylation specific PCR (MSP) assay. We selected 5 probes based on a random forest model, where 2 of the 5 probes are in common with the previously reported MGMT-STP27. The RF based model produced 93.5% concordance with MSP, as compared to STP-27, which showed 79% concordance. The discordant samples will be re-assessed with MSP assay to compare the accuracy of MSP with the 450K based approach. While further validation is in progress, this robust framework can efficiently identify additional methylation features correlated with MGMT methylation status and, data from the 450k array can be used to detect MGMT methylation status.
Can Automated Imaging for Optic Disc and Retinal Nerve Fiber Layer Analysis Aid Glaucoma Detection?
Authors: Katie Banister, Charles Boachie, Rupert Bourne, Jonathan Cook, Jennifer M. Burr, Craig Ramsay, David Garway-Heath, Joanne Gray, Peter McMeekin, Rodolfo Hernández, Augusto Azuara-Blanco
Journal: Ophthalmology (2016)
An Analysis of VTE Prophylaxis Practice in Oncology Patients after Implementation of a Standardized Mandatory Computerized Clinical Decision Support Tool
Authors: Anthony Serritella, Brandyn Daniel Lau, Elliott R Haut, Peggy S Kraus, Deborah Hobson, Dauryne Shaffer, Victor O Popoola, Kenneth Shermock, Sophie Lanzkron, Michael B. Streiff
Journal: Blood (2014)
Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome
Authors: Corinne Miceli-Richard, Shu-Fang Wang-Renault, Saida Boudaoud, Florence Busato, Céline Lallemand, Kevin Bethune, Rakiba Belkhir, Gaétane Nocturne, Xavier Mariette, Jörg Tost
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Beyond genetics, epigenetics alterations and especially those related to DNA methylation, play key roles in the pathogenesis of autoimmune diseases such as primary Sjögren9s syndrome (pSS) and systemic lupus erythematosus. This study aimed to assess the role of methylation deregulation in pSS pathogeny through a genome-wide methylation approach. <h3>Patients and methods</h3> 26 female patients with pSS and 22 age-matched controls were included in this study. CD4+ T cells and CD19+ B cells were isolated from peripheral blood mononuclear cells by magnetic microbeads and their genome-wide DNA methylation profiles were analysed using Infinium Human Methylation 450 K BeadChips. Probes with a median DNA methylation difference of at least 7% and p&lt;0.01 between patients and controls were considered significantly differentially methylated. <h3>Results</h3> Methylation alterations were mainly present in B cells compared with T cells. In B cells, an enrichment of genes with differentially methylated probes in genetic at-risk loci was observed, suggesting involvement of both genetic and epigenetic abnormalities in the same genes. Methylation alterations in B cells were more frequent in some specific pathways including Interferon Regulated Genes, mainly among patients who were autoantibody positive. Moreover, genes with differentially methylated probes were over-represented in B cells from patients with active disease. <h3>Conclusions</h3> This study demonstrated more important deregulation of DNA methylation patterns in B cells compared with T cells, emphasising the importance of B cells in the pathogenesis of the disease. Overlap between genes with differentially methylated probes in B lymphocytes and genetic at-risk loci is a new finding highlighting their importance in pSS.
Calciferol for Cutaneous Tuberculosis
Authors: G. D. Powell, P. R. Pearsall, J. E. M. Wigley
Journal: BMJ (1948)

BACTERICIDAL ACTION OF STREPTOMYCIN alJsUiRN 2. It seems possible that the therapeutic effects of streptomycin are due to bactericidal rather than to bacteriostatic action.This is certainly so when high concentrations are attained locally, as in the treatment of infections of the urinary tract.The streptomycin used in this work (streptomycin hydrochloride Merck) was supplied for studies in this hospital by the Streptomycin (Non-tuberculous Conditions) Clinical Trials Committee of the Medi- cal Research Council, to whom I express my thanks.I am indebted for valuable technical assistance to Miss P. M.
Chemotherapy at the end of life in metastatic lung cancer
Authors: B. E. Martin, H. Rajab, C. O. Ruud
Journal: Journal of Clinical Oncology (2008)

20663 Background: Proper patient selection in metastatic lung cancer chemotherapy assures palliation. A survey of community oncology practices found 43% of nonsmall cell lung cancer patients receiving chemotherapy in the last 31 days of life. (Oncologist 2006;11:1095). This group does not benefit from chemotherapy. Methods: Ninety-seven consecutive cases with Stage IV lung cancer in 2000 at Scott and White Clinic identified by the American College of Surgeons Tumor registry (ACOS) were retrospectively reviewed. The electronic medical record was queried in regard to chemotherapy use and brain metastasis in each case. Sixteen patients were excluded from analysis: no Pathology-3, transfer to another institution for terminal care-5, single visit for 2nd opinion-4, autopsy diagnosis-1, and not lung cancer- 3 (carcinoid-1, head and neck-1, unknown primary-1). The remaining 81 cases form this analysis. Results: See table. Conclusions: Clinical characteristics can be acquired from ACOS and can easily be integrated with information from the medical record. This method can be used acquire the % of patients receiving chemotherapy in the last 31 days of life and correlate with prognostic determinates. This metric can be used to measure interventions designed to limit futile chemotherapy in metastatic cancer. Group Number of Patients in Group Entire Group % Mean Survival (Days) Survival Range (Days) Patients Treated Last 31 Days Treated Last 31 Days % Group Total Metastatic Lung 81 100% 198 1-1740 11 14% Small Cell 17 21% 131 6-718 5 29% Non Small Cell 64 79% 216 1-1740 6 9% No Chemo 39 48% 68 1-477 NA NA Chemo 42 52% 320 7-1740 11 26% 1 Regimen 31 38% 201 7-821 8 26% >1 Regimen 11 14% 646 112-1740 3 27% Brain Metastasis 27 33% 124 6-604 3 11% Age > 69 44 54% 233 4-1740 3 7% No significant financial relationships to disclose.
Delayed daily filgrastim compared to early alternate day filgrastim following autologous peripheral blood stem cell transplantation for multiple myeloma
Authors: A. Iqbal, T. Motiwala, S. Badin, S. D. Rowley, M. L. Donato, D. S. Siegel, N. Lendvai, S. Hamarman, A. L. Pecora, S. L. Goldberg
Journal: Journal of Clinical Oncology (2008)

18015 Background: High-dose chemotherapy with autologous peripheral blood stem cell rescue has become a standard therapy in newly diagnosed multiple myeloma. To reduce the duration of neutropenia and risk of infections filgrastim is commonly administered post- transplantation. A large national trial in myeloma utilized melphalan 200 mg/m2 on day -2 followed by G-CSF daily beginning day +5. However, at Hackensack University Medical Center we have used the same chemotherapy on day -1 with G-CSF given on alternate days beginning day +3 (and daily on day +10). Methods: A retrospective review of all autologous peripheral blood stem cell transplants for myeloma performed between January 1, 2005 and March 31, 2007. All received prophylactic antibiotics consisting of ciprofloxacin, acyclovir, and fluconazole. Results: 24 patients were treated on the national trial using the delayed daily (DD) G-CSF schedule. 210 patients received the early alternate (EA) G-CSF schedule. The DD cohort (national trial) was younger than our institutional cohort (DD 48.0 ± 10.4 years vs. EA 59.3 ± 9.0 years, p<0.01; t = 5.7). The median PBSC CD34+ stem cell infused dose was similar (DD 7.06 ± 4.8 × 106/kg vs. EA 5.88 ± 2.8 × 106/kg, p=0.24; t=1.17). The median time to engraftment (ANC > 1.0) post- transplant was similar (DD 11.8 ± 2.0 days vs. EA 12.3 ± 2.8 days, p=0.39; t=0.86). The number of G-CSF injections administered was similar (DD 7.1 ± 0.8 vs. EA 6.5 ± 2.1, p = 0.17; t = 1.38). The rates of neutropenic fever (temperature > 100.5F) were similar (DD 50% vs. EA 57%, p = 0.66; z = 0.44). The rates of documented bacteremia were similar (DD 4.2% vs. EA 8.6%, p = 0.72; z = 0.35), including 8 enterococcal, 7 streptococcal, 3 E. coli, and 1 MRSA bacteremias. The number of days of non-prophylactic antibiotics (either for neutropenic fever or documented infection) was also similar (DD 2.65 ± 3.5 days vs. EA 1.58 ± 1.8 days, p = 0.14; t = 1.47). Conclusions: Delaying filgrastim dosing until day 5 following autologous stem cell infusion in melphalan based multiple myeloma transplants did not adversely affect clinical outcomes. Given the low rates of documented infection and short engraftment times, cost cutting measures such as further delays in G-CSF administration should be explored. No significant financial relationships to disclose.
Metastatic Properties Conferred on Nonmetastatic Tumors by Hybridization of Spleen B-Lymphocytes With Plasmacytoma Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: P De Baetselier, E Gorelik, Z Eshhar, Y Ron, S Katzav, M Feldman, S Segal
Journal: JNCI Journal of the National Cancer Institute (1981)

The P3-NSI/1-Ag4-1 (NSI) plasmacytoma, when transplanted sc in syngeneic BALB/c mice, grows locally without forming spontaneous metastases. We tested whether somatic hybridization of the NSI cells with spleen B-lymphocytes would render them metastatic in (C57BL/6 × BALB/c)F1 mice. We found that the hybridomas thus produced generated spontaneous metastases with distinct organ specificities. Some hybridomas produced metastases in both liver and spleen, whereas others produced metastases in only the liver. Cells derived from spleen-and liver-seeking hybridomas, when transplanted sc, produced tumors that metastasized to both the liver and spleen. Tumor cells derived from spleen metastasis produced, on transplantation, a tumor that generated spleen metastasis of a larger mass than did tumors derived from liver metastases. Cells derived from liver-seeking hybridomas metastasized to only the liver. Similar patterns of organ specificity were observed after iv injection of the hybridoma cells. The spleen seemed to play a determining role in controlling the production of liver metastases by hybridomas that produced both liver and spleen metastases. Such hybridomas did not produce liver metastases when injected into splenectomized recipients. Hybridomas that were only liver-seeking did produce metastases in splenectomized recipients.
Microrna-89 Expression As a Promising Prognostic Biomarker for Advanced Colorectal Cancer
Authors: N. Kubota, T. Nagasaka, Y. Umeda, Y. Mori, K. Kimura, F. Taniguchi, H. Tanioka, T. Fujiwara, A. Goel
Journal: Annals of Oncology (2014)
Cancer Imaging: pH-Activatable MnO-Based Fluorescence and Magnetic Resonance Bimodal Nanoprobe for Cancer Imaging (Adv. Healthcare Mater. 6/2016)
Authors: Benedict You Wei Hsu, Michael Ng, Aaron Tan, John Connell, Thomas Roberts, Mark Lythgoe, Yu Zhang, Siew Yee Wong, Kishore Bhakoo, Alexander M. Seifalian, Xu Li, John Wang
Journal: Advanced Healthcare Materials (2016)

On page 721, X. Li, J. Wang, and co-workers report on a MnO-based fluorescence/MRI dual-modality nanoprobe for cancer imaging. While the encapsulated MnO nanoparticles can quench the fluorophores effectively prior to cellular uptake, fluorescence activation is triggered upon dissolution of the MnO nanoparticles to release Mn2+ ions in the acidic lysosomal compartment of the cancer cells.
Problems Raised by the Search for Virus Particles in Human Leukemia. A Study With the Electron Microscope of Blood Plasma, Cerebrospinal Fluid, and Megakaryocytes From Bone Marrow&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Jacqueline Arnoult, Francoise Haguenau
Journal: JNCI Journal of the National Cancer Institute (1966)

Examination of 20 pellets from plasma and 7 pellets from cerebrospinal fluid of patients with leukemia revealed particles that could not be confirmed as viruses. Because of the difficulties inherent to morphological identification of some lypes of viruses with the negative-contrast technique, an attempt was made to find virus particles in ultrathin sections of megakaryocytes of human leukemic bone marrow, since megakaryocytes are the site of virus accumulation in some types of murine leukemia. About 300 megakaryocytes from 7 chronic leukemia patients and 5 controls (2 with normal marrows and 3 with thrombocytopenic purpuras) were examined in the electron microscope. No virus particles were found. But there were many virus-like particles, and it is shown that they corresponded to specific granules. Various cytological features of the megakaryocytes of these leukemic cases are discussed. None is specific for the leukemic state.
Tricyclic nonresponders: phenomenology and treatment
Authors: S P Roose, A H Glassman, B T Walsh, S Woodring
Journal: American Journal of Psychiatry (1986)

In an attempt to identify characteristics of tricyclic antidepressant nonresponders, the authors reviewed the records of inpatients with unipolar, nondelusional depression who had received adequate treatment (confirmed by plasma level determination) with tricyclics. The 17 patients who failed to respond were compared to a group of tricyclic responders with respect to demographic and phenomenologic variables. Although the nonresponders tended to have more previous episodes of depression and higher anxiety scores on the pretreatment Hamilton scale than the responders, they could not be distinguished from the responders by clinical or demographic data. All of the patients who failed to respond to tricyclics subsequently responded to monoamine oxidase inhibitors and/or ECT.
MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer
Authors: M.C. Piccirillo, G. Scambia, D. Lorusso, U. De Giorgi, M.O. Nicoletto, R. Lauria, A. Mosconi, C. Sacco, C. Omarini, P. Tagliaferri, G. Ferrandina, S. Cinieri, C. Pisano, S.C. Cecere, M. Di Napoli, V. Salutari, G. Daniele, C. Gallo, F. Perrone, S. Pignata
Journal: Annals of Oncology (2015)
Recent Progress of Microfluidics in Translational Applications
Authors: Zongbin Liu, Xin Han, Lidong Qin
Journal: Advanced Healthcare Materials (2016)

Microfluidics, featuring microfabricated structures, is a technology for manipulating fluids at the micrometer scale. The small dimension and flexibility of microfluidic systems are ideal for mimicking molecular and cellular microenvironment, and show great potential in translational research and development. Here, the recent progress of microfluidics in biological and biomedical applications, including molecular analysis, cellular analysis, and chip‐based material delivery and biomimetic design is presented. The potential future developments in the translational microfluidics field are also discussed.
Depressive personality in nonclinical subjects
Authors: D N Klein, G A Miller
Journal: American Journal of Psychiatry (1993)

This study explored the reliability and clinical correlates of the depressive personality in nonclinical subjects. In particular, the authors were interested in determining the relationship between depressive personality and mood disorders.The subjects were 185 college students who were selected by using a battery of screening inventories assessing a variety of psychopathological symptoms and traits. The subjects were given structured diagnostic interviews that included a section on depressive temperament.There were significant relationships between depressive personality and lifetime. DSM-III diagnoses of major depression and dysthymia. However, the magnitude of the associations was modest, indicating that these are distinct, although overlapping constructs. In addition, the subjects with depressive personality (N = 36) had significantly greater impairment and a higher rate of mood disorders in their first-degree relatives than did the subjects without depressive personality (N = 149). Moreover, these results were evident even after the subjects with a lifetime history of mood disorder were excluded.These data suggest that depressive personality is a clinically important condition that is not subsumed by existing mood disorders categories but can be viewed as falling within the affective spectrum.